Synthesis of Diversely Substituted Diethyl (Pyrrolidin-2-Yl)Phosphonates

Imidazoline I receptors (I-IR) are untapped therapeutic targets lacking a structural description. Although the levels of I-IR are dysregulated in a plethora of illnesses, the arsenal of ligands that can modulate I-IR is limited. In this framework, we have reported several new structural families emb...

Descripción completa

Detalles Bibliográficos
Autores: Bagán, Andrea, López-Ruiz, Alba, Abás, Sònia|||0000-0002-3005-3539, Molins Grau, Elies|||0000-0003-1012-0551, Pérez, Belén|||0000-0001-5801-1704, Muneta-Arrate, Itziar, Callado, Luis F.|||0000-0001-9941-012X, Escolano, Carmen|||0000-0002-9117-8239
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:312157
Acceso en línea:https://ddd.uab.cat/record/312157
https://dx.doi.org/urn:doi:10.3390/molecules30092078
Access Level:acceso abierto
Palabra clave:α-aminophosphonate
Pyrroline
Phosphonic ester
(Pyrrolidine-2-yl)phosphonate
Phosphoproline
Imidazoline I2 receptor ligand
Descripción
Sumario:Imidazoline I receptors (I-IR) are untapped therapeutic targets lacking a structural description. Although the levels of I-IR are dysregulated in a plethora of illnesses, the arsenal of ligands that can modulate I-IR is limited. In this framework, we have reported several new structural families embodying the iminophosphonate functional group that have an excellent affinity and selectivity for I-IR, and selected members have demonstrated relevant pharmacological properties in murine models of neurodegeneration and Alzheimer's disease. Starting with these iminophosphonates, we continued to exploit their high degree of functionalization through a short and efficient synthesis to access unprecedented 2,3-di, 2,2,3-tri, 2,3,4-tri, and 2,2,3,4-tetrasubstituted diethyl (pyrrolidine-2-yl) phosphonates. The stereochemistry of the new compounds was unequivocally characterized by X-ray crystallographic analyses. Two selected compounds with structural features shared with the starting products were pharmacologically evaluated, allowing us to deduce the required key structural motifs for biologically active aminophosphonate derivatives.